<div id="readability-page-1"><p>XTX Topco Ltd cut its stake in shares of  Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 84.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,009 shares of the company's stock after selling 5,327 shares during the period. XTX Topco Ltd's holdings in Medpace were worth $317,000 as of its most recent filing with the SEC.</p><ul><li>Can Medpace Stock Keep up this Pace?</li></ul><p>Several other institutional investors have also recently made changes to their positions in the stock. Mawer Investment Management Ltd. grew its stake in shares of  Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock valued at $256,559,000 after buying an additional 121,213 shares in the last quarter.  JPMorgan Chase &amp; Co. raised its position in  Medpace by 79.3% during the second quarter. JPMorgan Chase &amp; Co. now owns 265,270 shares of the company's stock worth $83,258,000 after acquiring an additional 117,301 shares in the last quarter.  Jacobs Levy Equity Management Inc. lifted its stake in  Medpace by 675.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock valued at $37,009,000 after acquiring an additional 105,807 shares during the last quarter.  Invesco Ltd. grew its position in shares of  Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after acquiring an additional 102,015 shares during the period.  Finally, Northern Trust Corp increased its stake in shares of  Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company's stock worth $102,830,000 after purchasing an additional 89,347 shares during the last quarter. Institutional investors and hedge funds own  77.98% of the company's stock. </p><h2>Insider Buying and Selling at Medpace</h2><p>In other news, CEO August J. Troendle sold 668 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares of the company's stock, valued at $381,694,426.96. This represents a 0.10% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, VP Susan E. Burwig sold 20,000 shares of the business's stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company's stock, valued at $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 387,925 shares of company stock valued at $233,386,647. Corporate insiders own  20.30% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research firms recently commented on MEDP. Weiss Ratings  reiterated a &#34;buy (b)&#34; rating on shares of Medpace in a report on Friday, October 31st. Mizuho lifted their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 24th. Zacks Research upgraded Medpace from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, October 27th. Cowen  reissued a &#34;sell&#34; rating on shares of Medpace in a report on Friday, October 24th. Finally, Wall Street Zen raised shares of Medpace from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, October 25th. One investment analyst  has rated the stock with a Strong Buy rating, two have issued  a Buy rating, ten have issued  a Hold rating and four have issued  a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $487.18.</p><p><b>Read Our Latest Research Report on MEDP</b></p><h2>Medpace Stock Performance</h2><p>NASDAQ MEDP opened at $548.12 on Monday. The stock has a market cap of $15.44 billion, a PE ratio of 38.33, a PEG ratio of 2.06 and a beta of 1.43. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26. The firm's fifty day moving average price is $567.90 and its two-hundred day moving average price is $454.82. </p><p>Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to analysts' expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the prior year, the company posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS.  As a group, sell-side analysts predict that  Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year. </p><h2>About Medpace</h2> (Free Report)<p>Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Medpace</li><li>What is a penny stock? A comprehensive guide</li><li>Broadcom’s Biggest Test Yet: Will Q4 Earnings Spark Another Rally?</li><li>What Are Earnings Reports?</li><li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li><li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li><li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li></ul><p><strong>Want to see what other hedge funds are holding MEDP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medpace Right Now?</h2><p>Before you consider Medpace, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p><p>While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MEDP

<p>XTX Topco Ltd reduced its stake in Medpace Holdings, Inc. by 84.1% in Q2, selling 5,327 shares and retaining 1,009 shares valued at $317,000. Other institutional investors like Mawer Investment and JPMorgan Chase increased their stakes. Medpace's stock has a consensus 'Hold' rating with a target price of $487.18. Insiders sold 387,925 shares worth $233.39 million in the last 90 days.</p>

XTX Topco Ltd Sells 5,327 Shares of Medpace Holdings, Inc. $MEDP